Analytical Data
-
基因名
Coagulation Factor XI/F11
- Application
-
别名
FXI; PTA; Fletcher Factor; Prekallikrein; Plasma Thromboplastin Antecedent
-
种属
Mouse
-
表达系统
E. coli
-
标签
N-His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q91Y47
-
表达区间
Pro157~Arg389
-
分子量
30kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Coagulation Factor XI (F11) is a crucial component of the intrinsic pathway of blood coagulation, playing a significant role in the formation of blood clots. Its deficiency is associated with a bleeding disorder known as hemophilia C, characterized by a reduced ability to form stable blood clots. Recent studies have highlighted the potential of recombinant Factor XI proteins as therapeutic agents for managing bleeding disorders, particularly given the advances in biotechnology that allow the production of such proteins in a more controlled and efficient manner. Recombinant Factor XI is being investigated not only for its therapeutic benefits in hemophilia C but also for its role in potentially reducing thrombotic events in patients at high risk for complications. The duality of Factor XI's function—promoting coagulation while also being involved in the pathogenesis of thrombosis—presents challenges and opportunities in its application. Ongoing research aims to elucidate the structure-function relationship of Factor XI, optimize recombinant production methods, and assess the safety and efficacy of therapeutic interventions targeting F11, ultimately contributing to improved clinical outcomes for patients with bleeding disorders and those susceptible to thrombotic complications.
